Eloxx Pharmaceuticals, Inc.SEC Filings
|
|
All SEC filings by Eloxx Pharmaceuticals, Inc. (ELOX) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 11, 2026 | |
| 10-Q | Quarterly report | View Diff | May 4, 2026 | |
| 10-K | Annual report | View Diff | Mar 16, 2026 | |
| NT 10-Q | Notice of late quarterly filing | Aug 14, 2025 | ||
| NT 10-Q | Notice of late quarterly filing | May 15, 2025 | ||
| NT 10-K | Notice of late annual filing | Apr 1, 2025 | ||
| NT 10-Q | Notice of late quarterly filing | Nov 19, 2024 | ||
| NT 10-Q | Notice of late quarterly filing | Aug 14, 2024 | ||
| NT 10-Q | Notice of late quarterly filing | May 15, 2024 | ||
| NT 10-K | Notice of late annual filing | Apr 1, 2024 |
Events
| 8-K | Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update | Aug 11, 2026 | ||
| 8-K | Current report | Jun 1, 2026 | ||
| 8-K | Submission of Matters to a Vote of Security Holders | May 1, 2026 | ||
| 8-K | Departure of Directors or Certain Officers | Aug 12, 2025 | ||
| 8-K | Departure of Directors or Certain Officers | Oct 17, 2024 | ||
| 8-K | Entry Into a Material Definitive Agreement | Jul 16, 2024 | ||
| 8-K | Departure of Directors or Certain Officers | Mar 29, 2024 | ||
| 8-K | Entry Into a Material Definitive Agreement | Mar 14, 2024 | ||
| 8-K | Entry Into a Material Definitive Agreement | Jan 9, 2024 | ||
| 8-K | Departure of Directors or Certain Officers | Dec 28, 2023 |
Registrations and Prospectuses
| 424B4 | Prospectus supplement with pricing info | Jun 9, 2026 | ||
| S-1/A | IPO registration | View Diff | Jun 4, 2026 | |
| 8-A12B | Registration of securities on exchange | Jun 1, 2026 | ||
| S-1/A | IPO registration | View Diff | Jun 1, 2026 | |
| S-1 | IPO registration | May 7, 2026 | ||
| DRS | Draft registration statement | Mar 20, 2026 | ||
| 25-NSE | Exchange delisting | Mar 21, 2024 | ||
| S-3 | Shelf registration | View Diff | Jan 24, 2024 | |
| S-8 | Registration of securities for employees | Jan 24, 2024 | ||
| 424B5 | Prospectus supplement for primary offering | Sep 20, 2023 |
Proxies
| DEF 14C | Information statement | May 8, 2026 | ||
| PRE 14C | Preliminary information | Apr 28, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 28, 2023 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 28, 2023 | |
| DEF 14A | Definitive proxy | View Diff | Oct 31, 2022 | |
| PRE 14A | Preliminary proxy | Oct 17, 2022 | ||
| DEFA14A | Additional proxy soliciting materials | Apr 29, 2022 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 29, 2022 | |
| DEFA14A | Additional proxy soliciting materials | Apr 1, 2021 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 1, 2021 |
Other
| EFFECT | Notice of effectiveness | Jun 9, 2026 | ||
| CERT | Certification of approval for exchange listing | Jun 8, 2026 | ||
| SEC STAFF ACTION | SEC staff action: Order | Feb 21, 2025 | ||
| CT ORDER | Confidential treatment order | Apr 24, 2023 | ||
| EFFECT | Notice of effectiveness | Aug 31, 2021 | ||
| CORRESP | Correspondence with SEC | Aug 26, 2021 | ||
| UPLOAD | Letter from SEC | Aug 26, 2021 | ||
| EFFECT | Notice of effectiveness | Nov 27, 2018 | ||
| CORRESP | Correspondence with SEC | Nov 21, 2018 | ||
| UPLOAD | Letter from SEC | Nov 20, 2018 |
Ownership
| SC 13G | Samsara Biocapital, L.p. Acquires Stake in Eloxx Pharmaceuticals, Inc. | Aug 14, 2026 | ||
| SC 13G | Beneficial ownership report | Aug 14, 2026 | ||
| SC 13G | Beneficial ownership report | Jul 27, 2026 | ||
| SC 13G | Beneficial ownership report | Jun 17, 2026 | ||
| SC 13G | Beneficial ownership report | Jun 17, 2026 | ||
| 4 | Domicilium Real Estate Fund Iii Lp | Jun 17, 2026 | ||
| 3 | Domicilium Real Estate Fund Iii Lp | Jun 17, 2026 | ||
| SC 13G | Beneficial ownership report | Jun 16, 2026 | ||
| SC 13G | Beneficial ownership report | Jun 16, 2026 | ||
| SC 13G | Beneficial ownership report | Jun 15, 2026 |